5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanomaJ. M. G. Larkin, V. Chiarion-Sileni,R. Gonzalez,J. J. Grob, P. Rutkowski,C. Lao,C. L. Cowey,D. Schadendorf,J. Wagstaff,R. Dummer,P. F. Ferrucci,M. Smylie, D. Hogg,A. Hill,I. Marquez-Rodas,J. B. A. G. Haanen, J. Rizzo,A. Balogh,F. S. Hodi,J. WolchokAnnals of Oncology（2019）引用 22|浏览106暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
